Search PubMed⌕ Search

Biomedical subjects

M K Shah

Publications and source records attributed to M K Shah.

At least 37 records · Page 2Linked to original sources
PubMed1998

A unique case of Cryptococcus laurentii keratitis spread by a rigid gas permeable contact lens in a patient with onychomycosis.

PURPOSE: We report the first case of fungal keratitis caused by Cryptococcus laurentii, a nonneoformans species. METHODS: A case of C. laurentii keratitis in a diabetic, gas permeable contact lens wearer was diagnosed after microbiologic evaluation of the corneal button after emergent keratoplasty. The excised cornea was also culture positive for Staphylococcus aureus and Fusarium solani. The medical history was significant for onychomycosis of the right great toe 2 months previously. Cultures of the toenail and of the contact lens case were also positive for C. laurentii and F. solani. RESULTS: An initial penetrating keratoplasty with histopathologically clear margins was unsuccessful in preventing intraocular spread of the fungal infection. Despite a repeat limbus-to-limbus therapeutic keratoplasty, pars plana vitrectomy, multiple anterior chamber washouts, intravitreal antifungal injections, and systemic antifungal treatment, the eye was ultimately lost due to ongoing inflammation, ocular hypotony, and a total retinal detachment. Histopathologic examination of the enucleated eye demonstrated filamentous fungi but no yeast forms. CONCLUSIONS: C. laurentii, a nonneoformans species, should be included in the differential diagnosis of fungal keratitis. This unique case also demonstrates the importance of a thorough clinical history and proper contact lens hygiene, particularly in a diabetic patient.

Antifungal Agents↗
PubMed1998

Treatment of symptomatic chronic adenotonsillar hypertrophy with amoxicillin/clavulanate potassium: short- and long-term results.

OBJECTIVE: To evaluate the short- and long-term effects of treatment of symptomatic chronic adenotonsillar hypertrophy (CATH) with a 30-day course of amoxicillin/clavulanate potassium (AMOX/CLAV). PATIENTS: Children 2 to 16 years of age with obstructive symptoms attributable to CATH, who did not have a history of recurrent adenotonsillitis. DESIGN: A prospective, randomized, double-blinded, placebo-controlled trial. SETTING: Ambulatory clinic of a tertiary care hospital. INTERVENTION: Patients were randomly treated with 30-day courses of either placebo (PLAC) or AMOX/CLAV (40 mg/kg in 3 divided doses daily). OUTCOME MEASURES: Patients' signs and symptoms were assessed by physical examination and by both physician and parental forced-choice questionnaires 1, 3, and 24 months after treatment. The decision to proceed to surgery or to continue expectant management was made for all patients by the same physician, based on reported symptoms and physical findings. RESULTS: Treatment with a 30-day course of AMOX/CLAV significantly reduced the need for surgery in the short term compared with PLAC (37.5% vs 62.7%) at 1-month follow-up). The reduced need for surgery in the AMOX/CLAV-treated group persisted at 3 months (AMOX/CLAV 54.5% vs PLAC 85.7%) and 24 months (AMOX/CLAV 83.3% vs PLAC 98.0%). CONCLUSIONS: A 30-day course of AMOX/CLAV significantly reduces the need for surgery in children with obstructive adenotonsillar hypertrophy at 1-month follow-up. This relative reduction persists at 3 and 24 months posttreatment, although the absolute percentages of patients requiring surgery increased in both groups as time after treatment increased. The reduction in symptoms in AMOX/CLAV-treated patients is modest but significant even in long-term follow-up. The precise role of this treatment for CATH is yet to be determined; however, our results suggest that a 30-day course of AMOX/CLAV can be used in situations when a temporary relief in symptoms is desirable or surgery would incur unacceptable risk.

Adenoids↗
PubMed1997

Comparison of responses to rat and human adrenomedullin in the hindlimb vascular bed of the cat.

Responses to rat (r) adrenomedullin (ADM) and human (h) ADM were compared in the hindlimb vascular bed of the cat under conditions of controlled blood flow. Intra-arterial injections of rADM and hADM in doses of 0.03-1 nmol caused dose-related decreases in hindlimb perfusion pressure. In terms of relative vasodilator activity, rADM was similar to hADM. The time course of the vasodilator response and the recovery half times (T1/2) for the vasodilator response to rADM and hADM were not significantly different. Decreases in hindlimb perfusion pressure in response to rADM and hADM were not altered by the calcitonin gene-related peptide receptor antagonist, rCGRP(8-37), at the same time, vasodilator responses to calcitonin gene-related peptide (CGRP) were significantly reduced. The T1/2 of the vasodilator response to rADM and hADM were significantly greater after administration of the cAMP-selective, type IV phosphodiesterase inhibitor, rolipram. These data demonstrate that decreases in hindlimb perfusion pressure in response to rADM and hADM are similar and that vasodilator responses to rADM are not dependent on the activation of CGRP receptors in the hindlimb vascular bed of the cat. These data further suggest that decreases in hindlimb perfusion pressure in response to rADM are mediated by smooth muscle increases in cAMP levels.

Adrenomedullin↗
PubMed1997

A case of tracheal obstruction during oesophageal removal of a foreign body.

A patient was admitted with an impacted foreign body in the oesophagus. Repeated attempts to remove it during oesophagoscopy proved difficult and caused obstruction of the trachea during manipulation of the foreign body. A smaller endotracheal tube was subsequently placed in the trachea relieving the obstruction.

Esophagoscopes↗
PubMed1997

Acute pain service, Kandang Kerbau Hospital, 1995--a first year's experience.

AIM: To determine the efficacy and safety of the different modes of post-operative analgesia in the first 24 hours for both caesarean section and major gynaecological procedures. METHODS: Being a purely descriptive study, the patients were not randomised to the post-operative analgesic mode. The choice was made both by the patient and the anaesthetist. The modes employed were continuous intravenous morphine, continuous intravenous pethidine, epidural morphine/bupivacaine, epidural bupivacaine/fentanyl and spinal morphine. During the first 24 hours, the patients' maximum pain scores, ability to sleep well, presence of nausea and/or vomiting, pruritus, respiratory depression and drowsiness and/or giddiness were elicited. Backache and inflammation at the site of insertion of the epidural catheter were also elicited in patients on regional analgesia. They were also asked if they were satisfied with the Pain Service. RESULTS: Out of 2,024 patients, 60% had undergone caesarean section and 40% had undergone major gynaecological procedures. Continuous intravenous morphine, the most common mode, was used in 83% of obstetric patients and 47.9% of gynaecological patients. Only one obstetric patients and one gynaecological patient complained of severe pain at rest while 12 obstetric patients and 3 gynaecological patients had severe pain on movement or coughing. Side-effects, most commonly nausea and/or vomiting and drowsiness and/or giddiness, were present in 8.8% of obstetric patients and 32.5% of gynaecological patients. 99.3% of obstetric patients and 99.6% of gynaecological patients were overall satisfied with their analgesia. CONCLUSION: Our post-operative analgesic modes were found to be effective and safe.

Analgesia↗
PubMed1992

Community-acquired methicillin-resistant Staphylococcus aureus infections in otolaryngology.

Soon after the introduction of methicillin, strains of Staphylococcus aureus resistant to methicillin were reported. Methicillin-resistant Staphylococcus aureus (MRSA) has become a common hospital pathogen, often resistant to multiple antibiotics, while causing significant morbidity and mortality. Community-acquired MRSA infections have been infrequently documented. Most reports have been associated with intravenous drug abuse. This report reviews 15 patients with community-acquired MRSA infections of the head and neck. None admitted to intravenous drug use. Additionally, no patient was known to be a healthcare worker. The MRSA strains showed antibiotic susceptibility and resistance profiles different from typical hospital-acquired MRSA isolates. All but one infection resolved with adequate surgical or appropriate antibiotic therapy. Clinicians should become aware of the possibility of community-acquired MRSA in the patient who has had continued infection despite antibiotic therapy.

Abscess↗
PubMed1991

Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis.

The source of infecting bacteria is often unknown in postoperative endophthalmitis. Using techniques of molecular epidemiology, the authors demonstrate that an organism isolated from the vitreous was genetically indistinguishable from an isolate recovered from the patient's eyelid, conjunctiva, or nose in 14 (82%) of 17 cases of endophthalmitis. In two cases of Staphylococcus epidermidis endophthalmitis, after cataract surgery was performed by the same surgeon on the same day, genetic analysis demonstrated that the infecting organisms from the two patients' vitreous were distinct, and, furthermore, that in each case the external isolates were indistinguishable from the vitreous isolate. The results implicate the patients' external tissues as the source of the infecting organism in those cases of acute postoperative endophthalmitis studied. Therefore, attention should be directed toward the external tissues and their microbial flora in the prophylaxis and prevention of postoperative bacterial endophthalmitis.

Aged↗
PubMed1988

In vitro effectiveness of 13 agents in otomycosis and review of the literature.

Many agents have been recommended for treating otomycosis, but no preparation has been widely accepted. To compare the effectiveness of many recommended preparations, we performed an in vitro study using 15 species of fungi and yeast cultured from patients presenting with otomycosis during the past year. By measuring zones of inhibition, we assessed the effectiveness of aqueous Merthiolate, Burow's solution (2%), VoSol HC, VoSol plain, Cortisporin suspension, clotrimazole 1%, Mycostatin, amphotericin B, ethanol 95%, miconazole, tolnaftate 1%, natamycin, and flucytosine. Most otic preparations showed little or no growth inhibition. However, Merthiolate was very effective against all organisms tested, clotrimazole was very effective against most yeast and fungi tested, and nystatin had the widest spectrum of activity among the antifungals. Tolnaftate was ineffective. Vigorous cleaning of the external auditory canal remains the mainstay in treating otymycosis, but proper laboratory identification and suitable topical therapy are also important in dealing with this capricious infection.

Antifungal Agents↗
PubMed1985

Phase II study of low-dose mitomycin in patients with ovarian cancer previously treated with chemotherapy.

Forty-three evaluable patients with ovarian cancer who had failed one or more chemotherapy regimens were treated with mitomycin iv at 28-day intervals. Thirty-six patients with good bone marrow reserve received 10 mg/m2 and seven patients with poor bone marrow reserve received 6.7 mg/m2 initially. Ten patients (23%) responded. Patients with an Eastern Cooperative Oncology Group performance status of 0-1 had better response rates and survivals as compared to patients with a performance status of 2-4 (44% vs 8%; median survival, 8 vs 4 months). The acute hematologic and gastrointestinal toxicity was minimal. No patients developed pulmonary, renal, cardiovascular, or local tissue toxicity.

Adult↗
PubMed1984

Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer.

Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at a dose of 130 mg/m2/day orally for 10 days every 6 weeks. Only one patient, with nodal and chest wall metastases, had a sustained complete regression; two patients had stable disease; and 35 patients had disease progression. The toxicity, which was primarily hematologic, was acceptable.

Adult↗
PubMed1983

An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer.

Ninety evaluable metastatic breast cancer patients refractory to hormonal therapy and combinations of cyclophosphamide, methotrexate, 5-fluorouracil, and doxorubicin were treated with a low-dose mitomycin regimen, i.e., 10 mg/m2 intravenously every 28 days. In order to minimize thrombocytopenia, dose de-escalations related to platelet counts were made. One patient (1%) had a complete response and 17% had partial responses for a median duration of 4 months. The time to progression for the responders and stabilized patients was similar; however, the responders and stabilized patients lived significantly longer than did the progressors. Hematologic toxicity was minimized because of planned de-escalations in mitomycin dosage. Perivenous ulceration, both immediate and delayed (8%), congestive heart failure (2%), and heart-renal failure with malignant hypertension (2%) resulted in significant morbidity, including two drug-related deaths. Although mitomycin dosages were successfully titrated according to platelet counts in this group of chemotherapy-refractory patients, prolonged use of this drug in adjuvant or early metastatic breast cancer patients is not recommended because of potentially irreversible thrombocytopenia.

Adult↗
PubMed1980

An effective low-dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients.

Sixty breast cancer patients with hormone-resistant metastatic disease who had progressed after chemotherapy with low-dose cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) or with L-phenylalanine mustard underwent treatment with a low-dose Adriamycin regimen,i.e., 20 mg/m2, intravenously on days 1 and 8 every 28 days. Two percent of patients had complete responses; 25%, partial responses; 38%, stabilization; and 35%, progression. The time to progression for the responders was similar to that of the stabilized patients, while the responders and stabilized patients survived significantly longer than did the progressors. Responses were seen in nodal, hepatic, dermal/subcutaneous, bone, pulmonary, and peritoneal metastases. The toxicity was mild: 18% of patients had leukocyte counts of less than 3,000/mm3; 10% had platelet counts of less than 90,000/mm3, 22% experience vomiting; and 33% had hair loss. No patient experienced local venous/subcutaneous toxicity or heart failure. Since this regimen of low-dose Adriamycin appears to be as effective as, but less toxic than, the secondary standard-dose of Adriamycin at 60--75 mg/m2 every three weeks, a randomized trial of low-dose Adriamycin vs. standard-dose Adriamycin should be conducted in metastatic breast cancer patients who have previously undergone chemotherapy.

Adult↗